BIOMIMESYS is an innovative hydrogel scaffold produced by HCS Pharma for 3D cell culture. It is made of hyaluronic acid and collagen, which mimic the extracellular matrix. Cells cultured in BIOMIMESYS form structures that closely resemble in vivo conditions. This allows cells to be studied under more physiologically relevant conditions for applications in drug development, metabolic studies, and cancer research. BIOMIMESYS is an easy to use, ready-to-use product suitable for various downstream applications and analysis techniques. It has been successfully used with many cancer cell lines.
BIOMIMESYS® Liver represents a new generation of mimetic HydroscaffoldS™ for 3D culture of hepatocyte-like cells. Available in a ready-to-use format, it enables the culture of hepatocytes and hepatocyte-like cells under physiological conditions that are representative of the microenvironment found in the liver. The highly porous nature of the Hydroscaffold™ allows the rapid uptake of nutrients, oxygen, etc. into the cells to create a reproducible study model for all downstream analyses used with 3D hepatocyte-like cell culture (metabolism, toxicity…).
Simplifying 3d cell culture generation for high content screening with BIOMIM...HCS Pharma
Growing interest in phenotypic screening, together with evidence that the drug response of cells grown in three-dimensional (3D) structures more closely resembles in vivo activity, has made high throughput, 3D fluorescence imaging an attractive screening option for drug discovery. However, creating 3D spheroids compatible with high content screening can be a difficult and expensive process.
BIOMIMESYS® is a range of patented hyaluronic acid scaffolds for 3D cell culture. They are made of RGDS- and galactosaminegrafted hyaluronic acid, using an adipic acid dihydrazide crosslinker and extracellular matrix proteins (eg. type I, IV or VI collagen) to accurately mimic the in vivo extracellular environment. BIOMIMESYS® is suitable for automated testing thanks to the uniform thickness of the scaffold – around 650 μm – with an average porosity of 100 to 200 μm
This application note describes a straightforward workflow for 3D cell seeding and spheroid formation using HCS Pharma’s BIOMIMESYS® plates in combination with INTEGRA’s VIAFLO 96/384 pipetting system. This process ensures rapid, controllable and reproducible 3D cell cultures, providing researchers with a highly efficient method to produce physiologically-relevant cellular models in a high throughput format
BIOMIMESYS® Adipose tissue represents a new generation of mimetic Hydroscaffold™ for 3D culture of adipocyte and adipocyte-like cells. Available in a ready-to-use format, it enables the culture of adipocytes and adipocyte-like cells under physiological conditions that are representative of the microenvironment found in adipose tissue. The highly porous nature of the scaffold allows the rapid uptake of nutrients, oxygen, etc. into the cells to create a reproducible study model for all downstream analyses used with 3D adipocyte cultures.
Importance of matricial and cellular microenvironments in in vitro models for...HCS Pharma
There is a 90% failure in clinical trials, due to efficacy and safety issues, which frequently concerns the central nervous system. That points a lack of relevance of preclinical models used upstream. In this frame, the aim of this study was to develop more relevant cerebral in vitro models, by including the matricial and cellular microenvironments, for drug discovery in Parkinson's disease.
HD available on https://hcs-pharma.com/poster---importance-of-matricial-and-cellular-microenvironments-in-in-vitro-models-for-drug-discovery-in-parkinsons-disease/
HCS Pharma extends its 3D cell culture range BIOMIMESYS® with BIOMIMESYS® BrainHCS Pharma
Following the success of BIOMIMESYS® range of products, which accurately and physiologically reproduces the microenvironment of liver, adipose and cancerous tissues, HCS Pharma is expanding its product range with BIOMIMESYS® Brain, an exclusive and innovative system for the 3D cell culture of neuronal cells.
BIOMIMESYS® Adipose tissue, a relevant in vitro adipocyte 3D modelHCS Pharma
BIOMIMESYS® range are hyaluronan based scaffolds developed to overcome the 2D flat culture limitations by recreating an in vivo physiology within the in vitro environment.
BIOMIMESYS® Adipocyte scaffold is made of RGDS-grafted Hyaluronic acid (1.6 MDa), Adipic acid dihydrazide crosslinker and extracellular matrix (ECM) proteins (collagen type I and collagen type VI) to mimic fat tissue-ECM composition.
Poster – Development and automation of 3D innovative hiPSC-based liver organo...HCS Pharma
We previously showed that human pluripotent stem cells (hiPSCs) provide a suitable model to study metabolic diseases upon hepatocyte-like cell (HLC) differentiation. In particular, HLCs have been used to model cholesterol metabolism regulation, by mimicking the main disease features in vitro. Human iPSCs can be generated from urine samples of patients with a well-described phenotype and carrying specific genotypes. This non-invasive approach allowed the study of LDLR- and PCSK9-mediated autosomal dominant hypercholesterolemia (ADH) as well as PCSK9-mediated familial hypobetalipoproteinemia (FHBL). While the direct link between hiPSCs and patients, as well as the abundance of HLCs provide promising advantages of such strategy, it is impaired mainly by the neonatal characteristic of HLCs as well as the difficulty to perform high throughput studies for pharmacological investigations.
BIOMIMESYS® Liver represents a new generation of mimetic HydroscaffoldS™ for 3D culture of hepatocyte-like cells. Available in a ready-to-use format, it enables the culture of hepatocytes and hepatocyte-like cells under physiological conditions that are representative of the microenvironment found in the liver. The highly porous nature of the Hydroscaffold™ allows the rapid uptake of nutrients, oxygen, etc. into the cells to create a reproducible study model for all downstream analyses used with 3D hepatocyte-like cell culture (metabolism, toxicity…).
Simplifying 3d cell culture generation for high content screening with BIOMIM...HCS Pharma
Growing interest in phenotypic screening, together with evidence that the drug response of cells grown in three-dimensional (3D) structures more closely resembles in vivo activity, has made high throughput, 3D fluorescence imaging an attractive screening option for drug discovery. However, creating 3D spheroids compatible with high content screening can be a difficult and expensive process.
BIOMIMESYS® is a range of patented hyaluronic acid scaffolds for 3D cell culture. They are made of RGDS- and galactosaminegrafted hyaluronic acid, using an adipic acid dihydrazide crosslinker and extracellular matrix proteins (eg. type I, IV or VI collagen) to accurately mimic the in vivo extracellular environment. BIOMIMESYS® is suitable for automated testing thanks to the uniform thickness of the scaffold – around 650 μm – with an average porosity of 100 to 200 μm
This application note describes a straightforward workflow for 3D cell seeding and spheroid formation using HCS Pharma’s BIOMIMESYS® plates in combination with INTEGRA’s VIAFLO 96/384 pipetting system. This process ensures rapid, controllable and reproducible 3D cell cultures, providing researchers with a highly efficient method to produce physiologically-relevant cellular models in a high throughput format
BIOMIMESYS® Adipose tissue represents a new generation of mimetic Hydroscaffold™ for 3D culture of adipocyte and adipocyte-like cells. Available in a ready-to-use format, it enables the culture of adipocytes and adipocyte-like cells under physiological conditions that are representative of the microenvironment found in adipose tissue. The highly porous nature of the scaffold allows the rapid uptake of nutrients, oxygen, etc. into the cells to create a reproducible study model for all downstream analyses used with 3D adipocyte cultures.
Importance of matricial and cellular microenvironments in in vitro models for...HCS Pharma
There is a 90% failure in clinical trials, due to efficacy and safety issues, which frequently concerns the central nervous system. That points a lack of relevance of preclinical models used upstream. In this frame, the aim of this study was to develop more relevant cerebral in vitro models, by including the matricial and cellular microenvironments, for drug discovery in Parkinson's disease.
HD available on https://hcs-pharma.com/poster---importance-of-matricial-and-cellular-microenvironments-in-in-vitro-models-for-drug-discovery-in-parkinsons-disease/
HCS Pharma extends its 3D cell culture range BIOMIMESYS® with BIOMIMESYS® BrainHCS Pharma
Following the success of BIOMIMESYS® range of products, which accurately and physiologically reproduces the microenvironment of liver, adipose and cancerous tissues, HCS Pharma is expanding its product range with BIOMIMESYS® Brain, an exclusive and innovative system for the 3D cell culture of neuronal cells.
BIOMIMESYS® Adipose tissue, a relevant in vitro adipocyte 3D modelHCS Pharma
BIOMIMESYS® range are hyaluronan based scaffolds developed to overcome the 2D flat culture limitations by recreating an in vivo physiology within the in vitro environment.
BIOMIMESYS® Adipocyte scaffold is made of RGDS-grafted Hyaluronic acid (1.6 MDa), Adipic acid dihydrazide crosslinker and extracellular matrix (ECM) proteins (collagen type I and collagen type VI) to mimic fat tissue-ECM composition.
Poster – Development and automation of 3D innovative hiPSC-based liver organo...HCS Pharma
We previously showed that human pluripotent stem cells (hiPSCs) provide a suitable model to study metabolic diseases upon hepatocyte-like cell (HLC) differentiation. In particular, HLCs have been used to model cholesterol metabolism regulation, by mimicking the main disease features in vitro. Human iPSCs can be generated from urine samples of patients with a well-described phenotype and carrying specific genotypes. This non-invasive approach allowed the study of LDLR- and PCSK9-mediated autosomal dominant hypercholesterolemia (ADH) as well as PCSK9-mediated familial hypobetalipoproteinemia (FHBL). While the direct link between hiPSCs and patients, as well as the abundance of HLCs provide promising advantages of such strategy, it is impaired mainly by the neonatal characteristic of HLCs as well as the difficulty to perform high throughput studies for pharmacological investigations.
Entosis is an interesting cell mechanism in which actually one cell can eat other cell and this can be helpful to combat the cancer. Future scopes are wide and lot more can be revealed in this.
Poster - A single procedure to generate functional hiPSCs-derived liver organ...HCS Pharma
metabolic diseases upon hepatocyte-like cell (HLC) differentiation. In particular, HLCs have been used to model cholesterol metabolism regulation, by mimicking the main disease features in vitro. Human iPSCs can be generated from urine samples of patients with a well-described phenotype and carrying specific genotypes. This non-invasive approach allowed the study of LDLR- and PCSK9-mediated autosomal dominant hypercholesterolemia (ADH) as well as PCSK9-mediated familial hypobetalipoproteinemia (FHBL). While the direct link between hiPSCs and patients, as well as the abundance of HLCs provide promising advantages of such strategy, it is impaired mainly by the neonatal characteristic of HLCs as well as the difficulty to perform high throughput studies for pharmacological investigations.
International Journal of Stem Cell Research and Transplantation (IJST) is an international, Open Access, peer-reviewed journal, which mainly focuses, on the advancements made in the field of cell biology, specifically in the field of Stem Cells.
International Journal of Stem Cell Research and Transplantation (IJST) ISSN:2328-3548, is a free, Open Access, Peer-reviewed, exclusive online journal covering areas of Stem cell research, translational work and Clinical studies in the specialty of Stem Cells and Transplantation including allied specialties relevant to the core subject, which is dedicated in publishing high quality manuscripts.
International Journal of Stem Cell Research and Transplantation (IJST) is a peer-reviewed journal, and is dedicated to providing information with respect to the latest advancements that are being upgraded in our everyday life with respect to the application of Stem cells.
BIOMIMESYS® Liver, a 3D cell culture model for maintaining and promoting hep...HCS Pharma
BIOMIMESYS® range are hyaluronan based hydroscaffold developed to overcome the 2D flat culture limitations by recreating an in vivo-like physiology within the in vitro environment.
BIOMIMESYS®Liver scaffold is made of RGDS and galactosamine-grafted Hyaluronic acid, Adipic acid dihydrazide crosslinker and extracellular matrix (ECM) proteins (collagen type I and collagen type IV) to mimic liver-ECM composition.
Poster - BIOMIMESYS® 3D hydroscaffold a matricial microenvironment for physio...HCS Pharma
How to make in vitro models predictive of in vivo conditions?
- By taking into account the 3D cellular organization of in vivo tissues
- By including the cellular and matricial microenvironments with BIOMIMESYS®
- By using OoC systems for dynamic in vivo-like in vitro systems
Dynamic models hold promise for future predictive microphysiological systems (MPS). By combining BIOMIMESYS® as an ECM surrogate for 3D culture, and hiPSC-derived cells, these dynamic microfluidic systems will revolutionize the field, reproducing human tissues and predict human outcomes.
Introduction
RBC
WBC
1. Granulocytes
Neutrophils
Eosinophil’s
Basophils
2. Agranulocytes
Lymphocytes
Monocyte
PLATELETS
Blood is a bright red, viscous, slightly alkaline fluid that accounts for approximately 7 % of total body weightThe average human has 5 litres of blood (Average Blood Volume is 4 to 6 liters).
It is a transporting fluid.
Red colour is due to the presence of oxyhaemoglobin.
Ph - 7.4 slightly alkaline.
Specific gravity - 1.060
Viscosity is 5 times greater then the water i.e thicker than water.
Blood is the only fluid tissue.
Blood is a complex connective tissue in which living cells, the formed elements, are suspended in fluid componenet called plasma.
A groundbreaking 3D cell culture technology for HCS: BIOMIMESYS hydroscaffoldHCS Pharma
Most potential drug candidates (90%) fail within the clinical trials, mainly because of lack of efficacy.
What if the pharmaceutical industry uses predictive human in vitro models in early drug discovery ?
Entosis is an interesting cell mechanism in which actually one cell can eat other cell and this can be helpful to combat the cancer. Future scopes are wide and lot more can be revealed in this.
Poster - A single procedure to generate functional hiPSCs-derived liver organ...HCS Pharma
metabolic diseases upon hepatocyte-like cell (HLC) differentiation. In particular, HLCs have been used to model cholesterol metabolism regulation, by mimicking the main disease features in vitro. Human iPSCs can be generated from urine samples of patients with a well-described phenotype and carrying specific genotypes. This non-invasive approach allowed the study of LDLR- and PCSK9-mediated autosomal dominant hypercholesterolemia (ADH) as well as PCSK9-mediated familial hypobetalipoproteinemia (FHBL). While the direct link between hiPSCs and patients, as well as the abundance of HLCs provide promising advantages of such strategy, it is impaired mainly by the neonatal characteristic of HLCs as well as the difficulty to perform high throughput studies for pharmacological investigations.
International Journal of Stem Cell Research and Transplantation (IJST) is an international, Open Access, peer-reviewed journal, which mainly focuses, on the advancements made in the field of cell biology, specifically in the field of Stem Cells.
International Journal of Stem Cell Research and Transplantation (IJST) ISSN:2328-3548, is a free, Open Access, Peer-reviewed, exclusive online journal covering areas of Stem cell research, translational work and Clinical studies in the specialty of Stem Cells and Transplantation including allied specialties relevant to the core subject, which is dedicated in publishing high quality manuscripts.
International Journal of Stem Cell Research and Transplantation (IJST) is a peer-reviewed journal, and is dedicated to providing information with respect to the latest advancements that are being upgraded in our everyday life with respect to the application of Stem cells.
BIOMIMESYS® Liver, a 3D cell culture model for maintaining and promoting hep...HCS Pharma
BIOMIMESYS® range are hyaluronan based hydroscaffold developed to overcome the 2D flat culture limitations by recreating an in vivo-like physiology within the in vitro environment.
BIOMIMESYS®Liver scaffold is made of RGDS and galactosamine-grafted Hyaluronic acid, Adipic acid dihydrazide crosslinker and extracellular matrix (ECM) proteins (collagen type I and collagen type IV) to mimic liver-ECM composition.
Poster - BIOMIMESYS® 3D hydroscaffold a matricial microenvironment for physio...HCS Pharma
How to make in vitro models predictive of in vivo conditions?
- By taking into account the 3D cellular organization of in vivo tissues
- By including the cellular and matricial microenvironments with BIOMIMESYS®
- By using OoC systems for dynamic in vivo-like in vitro systems
Dynamic models hold promise for future predictive microphysiological systems (MPS). By combining BIOMIMESYS® as an ECM surrogate for 3D culture, and hiPSC-derived cells, these dynamic microfluidic systems will revolutionize the field, reproducing human tissues and predict human outcomes.
Introduction
RBC
WBC
1. Granulocytes
Neutrophils
Eosinophil’s
Basophils
2. Agranulocytes
Lymphocytes
Monocyte
PLATELETS
Blood is a bright red, viscous, slightly alkaline fluid that accounts for approximately 7 % of total body weightThe average human has 5 litres of blood (Average Blood Volume is 4 to 6 liters).
It is a transporting fluid.
Red colour is due to the presence of oxyhaemoglobin.
Ph - 7.4 slightly alkaline.
Specific gravity - 1.060
Viscosity is 5 times greater then the water i.e thicker than water.
Blood is the only fluid tissue.
Blood is a complex connective tissue in which living cells, the formed elements, are suspended in fluid componenet called plasma.
A groundbreaking 3D cell culture technology for HCS: BIOMIMESYS hydroscaffoldHCS Pharma
Most potential drug candidates (90%) fail within the clinical trials, mainly because of lack of efficacy.
What if the pharmaceutical industry uses predictive human in vitro models in early drug discovery ?
Neuromics base presentation 2020 with Virus Transport MediaPete Shuster
Neuromics' is a leader in providing Biopharmas, Academic and Government with CFR compliant 2 and 3-D human primary cell assays, media and supplements for discovery. We also provide antibodies, proteins/growth factors, apoptosis kits and genetic engineering/manipulation tools. We now have FDA registered Virus Transport Media (VTM).
SCT60103 March 2017 Assignment - Group 3Yvonne Chin
Compare the use of Lonza KGM Gold Bullet kit and Rheinwald and Green complete FAD medium in primary human epidermal keratinocytes culture and the applicability of cells cultured by these medium in the construction of reconstituted skin equivalent model
Achieving High Yields in Scalable Xeno Free Culture Formats with Mesenchymal ...Merck Life Sciences
Watch the presentation of this webinar here: https://bit.ly/3ryE5ST
Optimize your mesenchymal stem cell growth. Join our webinar to learn more about our GMP-compliant xeno free media formulation that supports high performance expansions and compatibility with scalable xeno free manufacturing conditions.
Optimizing ex vivo cell expansion processes in preparation for clinical use is a critical step in cell therapy manufacturing. Given the curative and lifesaving impacts these therapies can have on patients, overcoming roadblocks with scalability and supply chain, using high quality raw materials are essential for therapeutic access.
The GMP-compliant Stemline® XF MSC Medium and cocktail promotes expansion of human mesenchymal stromal/stem cells (hMSCs) to high densities while maintaining cell identity and quality. This product was designed for derivation and expansion of MSCs using xeno free conditions in planar and microcarrier-based culture platforms, easing the transfer between research, clinical, and manufacturing scale cultures.
In this webinar, you will:
• Explore the current landscape and future trends of cell culture media for adult mesenchymal stem cells
• Discover ways to derive MSC's from Bone Marrow in Xeno Free conditions from static to microcarrier-based suspension culture platforms.
• Learn how Stemline® XF MSC Media provides robust performance and reduces scalability roadblocks
Presented by: Kathleen Ongena, Ph.D., Head of Customer Applications and Mark Ventresco, Cell Therapy Product Manager
Achieving High Yields in Scalable Xeno Free Culture Formats with Mesenchymal ...MilliporeSigma
Watch the presentation of this webinar here: https://bit.ly/3ryE5ST
Optimize your mesenchymal stem cell growth. Join our webinar to learn more about our GMP-compliant xeno free media formulation that supports high performance expansions and compatibility with scalable xeno free manufacturing conditions.
Optimizing ex vivo cell expansion processes in preparation for clinical use is a critical step in cell therapy manufacturing. Given the curative and lifesaving impacts these therapies can have on patients, overcoming roadblocks with scalability and supply chain, using high quality raw materials are essential for therapeutic access.
The GMP-compliant Stemline® XF MSC Medium and cocktail promotes expansion of human mesenchymal stromal/stem cells (hMSCs) to high densities while maintaining cell identity and quality. This product was designed for derivation and expansion of MSCs using xeno free conditions in planar and microcarrier-based culture platforms, easing the transfer between research, clinical, and manufacturing scale cultures.
In this webinar, you will:
• Explore the current landscape and future trends of cell culture media for adult mesenchymal stem cells
• Discover ways to derive MSC's from Bone Marrow in Xeno Free conditions from static to microcarrier-based suspension culture platforms.
• Learn how Stemline® XF MSC Media provides robust performance and reduces scalability roadblocks
Presented by: Kathleen Ongena, Ph.D., Head of Customer Applications and Mark Ventresco, Cell Therapy Product Manager
"A Nano-In-Micro System for Enhanced Stem Cell Therapy of Ischemic Diseases" is a research article published in ACS central science http://pubs.acs.org/journal/acscii
Normal tissues and tumors arise from a population of cells termed stem cells. In vivo experiments have provided evidence of the presence of stem cells throughout the mouse mammary gland. Premalignant mammary outgrowths that faithfully recapitulate the mammary epithelial cell lineage upon transplantation contain cells with tumor-forming potential. Cell sorting techniques have identified putative mouse mammary stem cell surface markers and human breast cancer stem cell surface markers. These markers do not identify only stem cells but in fact distinguish a mixed population of cells containing stem cell activity. Previous studies have demonstrated that clones arising from single cells in vitro can be categorized into three types based on the clone morphology. Here, we report the characterization, both in vitro and in vivo, of clonogenic cells from a non-tumorigenic mammary epithelial population and those from an erbB2-induced mammary tumor. We found that clones arising from normal mammary cells expressed different patterns of stem and developmental marker between the clone types and compared to the expression patterns observed on clones that developed from tumorigenic mammary cells.
The results of the study show a promising role of Acacia Honey, a natural product with proven therapeutic effects on skin wound healing. It accelerated the initial stage of corneal wound healing without the side effects found when using conventional treatments which contain preservatives. Corneal keratocytes cultured in media supplemented with 0.025% Acacia Honey showed an increase in proliferative capacity while retaining their morphology, gene and protein expressions with normal cell cycle.
A presentation on the Stem Cells 21 - IntelliHealthPlus medical center in Bangkok, Thailand. Information on Umbilical cord mesenchymal stem cells and Cd34+ cells, also the companies Ultrasound adipose stem cell separation.
BIOMIMESYS®Liver, a 3D cell culture model for maintaining and promoting hepat...HCS Pharma
BIOMIMESYS® range are hyaluronan based hydroscaffold developed to overcome the 2D flat culture limitations by recreating an in vivo-like physiology within the in vitro environment.
BIOMIMESYS®Liver hydroscaffold is made of RGDS and galactosamine-grafted Hyaluronic acid, Adipic acid dihydrazide crosslinker and extracellular matrix (ECM) proteins (collagen type I and collagen type IV) to mimic liver ECM composition.
Compare the use of Lonza KGM Gold Bullet kit and Rheinwald and Green complete FAD medium in primary human epidermal keratinocytes culture and its applicability cells cultured by these medium in the construction of reconstituted skin equivalent model
Poster HCSPHARMA (OncoLilleDays2022) - Mechanobiological characterization of ...HCS Pharma
Thomas Meynard, PhD student in OncoLille (under the supervision of Vincent Senez and Isabelle Van Seuningen) in collaboration with HCS Pharma too, presented a poster showing that it is possible to include BIOMIMESYS® in a microfluidic chip to co-culture Cancer-Associated fibroblasts and cancerous cells, with the aim to increase the complexity and the relevance of in vitro cancer models.
Poster : Development of personalized therapeutic targeting in lung cancer wit...HCS Pharma
Abstract: Lung cancer is one of the most frequent cancers in the world with a high mortality rate. The discovery of oncogenic alterations in these cancers allowed the development of targeted therapies against several receptor tyrosine kinases (RTK) including EGFR, ALK or MET and contributed to improve the prognosis of some patients. Mutations impacting the MET receptor exon 14 splice sites (METex14) have recently been detected in about 3% of lung cancers and lead to the loss of the juxtamembrane domain with several negative regulatory sites. METex14 does not lead to constitutive activation of the receptor but we demonstrated that HGF, its ligand, is required for the full development of the transforming capabilities of the METex14 receptor in SCID-HGFhuman transgenic mice.
Several clinical trials have shown that only half of METex14 patients responded to MET inhibitors. While encouraging, these results are lower than those obtained with other treatments such as EGFR inhibitors. Interestingly, METex14 mutations are frequently associated with other molecular alterations including PTEN loss or TP53 mutations. Furthermore, we have shown that many METex14 mutated patients have autocrine secretion of HGF ligand. Understanding how these co-alterations impact METex14 oncogenicity and sensitivity to existing therapies is of outmost importance to identify patients that could benefit from them.
Poster - Including the matricial tumoral microenvironment in 3D in vitro mode...HCS Pharma
In oncology, 97% of drug candidates fail in clinical trials. This highlights a lack of relevance of preclinical models used upstream. Indeed, human in vitro models don’t consider the Tumoral Extracellular Matrix (TECM). However, more and more studies demonstrate that ECM composition and stiffness are modified in tumors and are linked to cancer initiation, progression, propagation, and drug resistances.
BIOMIMESYS® is a Hyaluronic Acid-based matrix grafted with structural and adhesion molecules, which mimics the ECM/TECM. It is chemically defined and its composition and stiffness can be modified to reproduce the organ-specificity of the ECM, or to mimic a pathological microenvironment in vitro.
We have demonstrated that the exposition of colon cancer cells cultured in BIOMIMESYS® Oncology matrix to an anti-proliferative drug showed a closer in vitro/in vivo correlation in the EC50 curve compared to 2D culture. Cancer cells can be advantageously grown in BIOMIMESYS® for several weeks in multiwell plates and in microfluidic chips for more advanced models. We also observed that modifications in the matrix composition and stiffness modify the cell behavior. Moreover, thanks to collaborations with academic laboratories, we demonstrated that BIOMIMESYS® allows to reproduce in vitro the behavior of cancerous cells in vivo, like mutation effects and metastasis propagation, and could be a relevant alternative to animal models. These results showed that the matricial microenvironment modifies the cell behavior in vitro and should be considered carefully in drug discovery. BIOMIMESYS® hydroscaffold™ is adapted to High Content Screening and represented a powerful tool to better select drug candidate.
HCS PHARMA - (ECM 2022) Development of innovative hiPSC-based model including...HCS Pharma
<!-- wp:paragraph -->
<p>We previously showed that human pluripotent stem cells (hiPSCs) provide a suitable model to study<br>metabolic diseases upon hepatocyte-like cell (HLC) differentiation. With a non-invasive approach, hiPSCs can be generated from urine samples of patients and HLCs have been used to model cholesterol metabolism regulation, by the study of LDLR- and PCSK9-mediated autosomal dominant hypercholesterolemia (ADH) as well as PCSK9-mediated familial hypobetalipoproteinemia (FHBL). This model provides promising advantages with a direct link to the patient and with an unlimited source of HLCs. But like all models, there are limitations, mainly by the neonatal characteristic of HLCs lead to difficulties for pharmacological investigations.</p>
<!-- /wp:paragraph -->
<!-- wp:paragraph -->
<p>Therefore, to overcome these burdens, we chose to 1. Differentiate hiPSCs into HLCs in an innovative<br>3D <a href="https://hcs-pharma.com/biomimesys/">hyaluronic acid-based hydroscaffold</a>, BIOMIMESYS® produces by HCS Pharma to enhance their maturation. 2. Adapt our 3D differentiation process to a 96-well format to make it compatible for drug screening. 3. Characterization of the 3D HLCs model by metabolism tests and compare to primary human hepatocyte (PHH).</p>
<!-- /wp:paragraph -->
<!-- wp:paragraph -->
<p>We gathered 3’ SRP data all along the differentiation process and RNAseq has been performed by comparing 2D and 3D differentiation conditions to characterize hiPSCs differentiation into liver organoids. We observed an enhanced expression of most hepatic genes and genes expressed by non-parenchymal cells such as stellate cells. Immunofluorescence data confirmed the co-localization of albumin-positive<br>hepatocytes, desmin-positive stellate cells and LYVE1-positive endothelial cells in liver organoids. Finally, at a functional level, several CYP activities including CYP3A4 were detected at the basal level and successfully induced. Liver organoids responded to pharmacological treatments as shown by their ability to accumulate lipids upon amiodarone treatment or uptake LDL-bodipy upon statin treatment.</p>
<!-- /wp:paragraph -->
<!-- wp:paragraph -->
<p>Altogether, our development gave rise to functional liver organoids generated with a unique and common procedure, in a process of automating for future high throughput screening.</p>
<!-- /wp:paragraph -->
HCSPHARMA Importance of microenvironment in cerebral in vitro models for phen...HCS Pharma
Aim: About 90% of drug-candidates failed in clinical trials, in particular in neurology, due to a lack of efficacy. That highlights a lack of relevance in preclinical models, including in vitro models, which do not take into account the microenvironment, composed by glial cells and the Extracellular Matrix (ECM). The objective was to study the influence of the microenvironment in cerebral in vitro models, in the frame of Parkinson’s Disease (PD).
Methods: First, we analyzed the influence of astrocytes on Luhmes cell sensitivity, a dopaminergic neuronal cell line, in 2D culture. Then, we developed a hyaluronic acid-based hydroscaffold for 3D cell culture, which mimics the ECM, and study the sensitivity of Luhmes cells in this model. Thirdly, we performed a co-culture of Luhmes cells and astrocytes in this matrix, to form a complex model including both the glial and the matricial microenvironments.
Results: We observed a protective effect of astrocytes in 2D culture. In the hydroscaffold, Luhmes cells displayed a lower sensitivity compared to 2D culture, that was explained by a partial retention of toxic molecules in the matrix, and differences in neuronal protein expression. In the co-culture, we observed spheroids containing both neurons and astrocytes.
Conclusions: This work highlighted that the microenvironment of neurons can modify the neuronal response in vitro, and should thus be considered carefully in academic research and in drug discovery. This model can be now used to study the microenvironment modifications in pathological conditions, and to develop innovative drugs targeting the microenvironment.
Poster – Development and automation of 3D innovative hiPSC-based liver organo...HCS Pharma
We previously showed that human pluripotent stem cells (hiPSCs) provide a suitable model to study metabolic diseases upon hepatocyte-like cell (HLC) differentiation. In particular, HLCs have been used to model cholesterol metabolism regulation, by mimicking the main disease features in vitro. Human iPSCs can be generated from urine samples of patients with a well-described phenotype and carrying specific genotypes. This non-invasive approach allowed the study of LDLR- and PCSK9-mediated autosomal dominant hypercholesterolemia (ADH) as well as PCSK9-mediated familial hypobetalipoproteinemia (FHBL). While the direct link between hiPSCs and patients, as well as the abundance of HLCs provide promising advantages of such strategy, it is impaired mainly by the neonatal characteristic of HLCs as well as the difficulty to perform high throughput studies for pharmacological investigations.
Development of a new liver-on-chip including BIOMIMESYS® technology for mimic...HCS Pharma
Objective: to develop a new liver-on-chip model that includes a relevant 3D matrix for hepatic cell growth and function with the use of of BIOMIMESYS® Liver hydroscaffold for a physiological 3D hepatocyte culture.
HCS Pharma complète sa gamme de culture cellulaire en 3D BIOMIMESYS® avec BIO...HCS Pharma
Après le succès de la gamme BIOMIMESYS® reproduisant de manière précise et physiologique le microenvironnement du foie, des tissus adipeux et cancéreux, HCS Pharma étend sa gamme avec BIOMIMESYS® Brain, un système exclusif et innovant permettant la culture cellulaire en 3D de cellules neuronales.
3D innovative hiPSC-based models including the microenvironment for phenotyp...HCS Pharma
We previously showed that human pluripotent stem cells (hiPSCs) provide a suitable model to study metabolic diseases upon hepatocyte-like cell (HLC) differentiation. In particular, HLCs have been used to model cholesterol metabolism regulation, by mimicking the main disease features in vitro. Human iPSCs can be generated from urine samples of patients with a well-described phenotype and carrying specific genotypes. This non-invasive approach allowed the study of LDLR- and PCSK9-mediated autosomal dominant hypercholesterolemia (ADH) as well as PCSK9-mediated familial hypobetalipoproteinemia (FHBL). While the direct link between hiPSCs and patients, as well as the abundance of HLCs provide promising advantages of such strategy, it is impaired mainly by the neonatal characteristic of HLCs as well as the difficulty to perform high throughput studies for pharmacological investigations.
Therefore, to overcome these burdens, we choose to 1. Differentiate hiPSCs into HLCs in a 3D environment instead of the classical 2D culture systems to enhance their maturation; 2. Adapt our 3D differentiation process to a 96 wells format to make it compatible for drug screening.
To reach our goals, we established a partnership with HCS Pharma, which has an expertise in high content phenotypic screening and produces an innovative 3D scaffold, BiomimesysTM. This scaffold is composed of hyaluronic acid that can be functionalized with extra cellular matric derivatives, with adjustable stiffness and porosity. We setup conditions for hiPSCs seeding and differentiation to reach a new protocol adapted to a 3D environment. Our preliminary data indicate that our procedure enhanced expression of hepatic markers such as transcription factors (FOXA2, FOXA3, HNF1a, HNF1b, HNF4a), cytochrome P450 (CYP450) family members (CYP3A4, CYP2A6, CYP7A1) or cholesterol metabolism regulators (PCSK9, Lipoprotein(a)). During our presentation, we will discuss our data hiPSCs differentiation in 3D, CYP450 activities and induction, as well as their application for the study of metabolic diseases.
Neurotoxicity assessment: Comparison between SH-SY5Y and iPSC-derived cellsHCS Pharma
As shown by AstraZeneca in Nature reviews*, one third of the safety failures is linked to CNS toxicity during the clinical trials of drugs. Therefore, relevant in vitro human model is needed to detect early neurotoxicity of drug candidates. In this study, sensitivity of iPSC-derived neuronal cells to 32 compounds is compared to the sensitivity of SH-SY5Y cells. Two types of iPS-derived cells are tested: central nervous system cells (CNS.4U™ cells) and peripheral nervous system cells (PERI.4U™ cells) from Ncardia. Toxic effects are then measured by HCS cell imaging.
Présentation de HCS Pharma dans la gazette du laboratoire - 2017HCS Pharma
La société HCS Pharma, spécialiste de l’imagerie cellulaire à haut débit et du développement de nouveaux modèles cellulaires, est née à Rennes (35) en août 2014. Le 6 octobre dernier, elle a inauguré de nouvelles installations à Lille (59), au cœur du parc Eurasanté, et y a mis à l’honneur notamment sa toute nouvelle plate-forme robotique baptisée HAPIx, HCS Automation Platform for Imaging. Nathalie MAUBON, Présidente de l’entreprise, nous présente HCS Pharma et ses nouvelles ambitions portées par cette implantation lilloise, au plus proche des chercheurs et cliniciens en santé humaine...
Urine sample-derived human induced pluripotent stem cells as a model to study...HCS Pharma
Human induced pluripotent stem cells (hiPSC) are becoming a relevant model for the study of liver metabolic diseases once differentiated into hepatocyte-like cells (HLC), and it has been shown that they can faithfully recapitulate autosomal dominant hypercholesterolemia (ADH). PCSK9 is a critical modulator of cholesterol homeostasis, and quickly became a hot target for ADH pharmacological treatment strategies. However, current cellular models to further decipher the role of PCSK9 in ADH are limited, especially to study the PCSK9 gain of function mutation S127R, which seems to interfere with LDL cholesterol homeostasis intracellularly by still unknown mechanisms.
3D culture in phenotypic screening : advantages, process changes and new tech...HCS Pharma
It was a real pleasure to be in the « High-Content and Phenotypic Screening » meeting in Cambridge. We were invited by our partner Molecular Devices to give a talk during the "User meeting Molecular Devices" about our vision of 3D culture in phenotypic screening and the impact of new technologies. We also presented a poster about "Neurotoxicity assay on 2D and 3D culture using High Content Screening technology".
Neurotoxicity assay on 2D and 3D culture using High Content Screening (HCS) t...HCS Pharma
As shown by AstraZeneca in nature reviews*, one third of safety failures along the drug discovery process is linked to CNS toxicity uncovered in clinical trials. To avoid this attrition, the potential neurotoxicity of any drug going through the blood brain barrier (BBB) needs to be assessed in the very early stages of new chemical entities (NCE) research. Neurotoxicity assays can be performed on the SH-SY5Y human cell line by using High-Content Screening (HCS) technologies. The present study was performed using classical 2D and 3D culture protocols. In this poster, 2D results and preliminary 3D culture results on multiple reference compounds are depicted.
Augmented and Virtual Reality for the future of laboratoriesHCS Pharma
As you know, immersive technologies change many things in our way to work. Of course, biology and biotechnology companies are also concerned by this trend. In HCS Pharma, we use to explore these fields to improve the quality (and the readability) of our results. We think it's a natural behavior, to keep good relationships with our customers.
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdfAnujkumaranit
Artificial intelligence (AI) refers to the simulation of human intelligence processes by machines, especially computer systems. It encompasses tasks such as learning, reasoning, problem-solving, perception, and language understanding. AI technologies are revolutionizing various fields, from healthcare to finance, by enabling machines to perform tasks that typically require human intelligence.
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...i3 Health
i3 Health is pleased to make the speaker slides from this activity available for use as a non-accredited self-study or teaching resource.
This slide deck presented by Dr. Kami Maddocks, Professor-Clinical in the Division of Hematology and
Associate Division Director for Ambulatory Operations
The Ohio State University Comprehensive Cancer Center, will provide insight into new directions in targeted therapeutic approaches for older adults with mantle cell lymphoma.
STATEMENT OF NEED
Mantle cell lymphoma (MCL) is a rare, aggressive B-cell non-Hodgkin lymphoma (NHL) accounting for 5% to 7% of all lymphomas. Its prognosis ranges from indolent disease that does not require treatment for years to very aggressive disease, which is associated with poor survival (Silkenstedt et al, 2021). Typically, MCL is diagnosed at advanced stage and in older patients who cannot tolerate intensive therapy (NCCN, 2022). Although recent advances have slightly increased remission rates, recurrence and relapse remain very common, leading to a median overall survival between 3 and 6 years (LLS, 2021). Though there are several effective options, progress is still needed towards establishing an accepted frontline approach for MCL (Castellino et al, 2022). Treatment selection and management of MCL are complicated by the heterogeneity of prognosis, advanced age and comorbidities of patients, and lack of an established standard approach for treatment, making it vital that clinicians be familiar with the latest research and advances in this area. In this activity chaired by Michael Wang, MD, Professor in the Department of Lymphoma & Myeloma at MD Anderson Cancer Center, expert faculty will discuss prognostic factors informing treatment, the promising results of recent trials in new therapeutic approaches, and the implications of treatment resistance in therapeutic selection for MCL.
Target Audience
Hematology/oncology fellows, attending faculty, and other health care professionals involved in the treatment of patients with mantle cell lymphoma (MCL).
Learning Objectives
1.) Identify clinical and biological prognostic factors that can guide treatment decision making for older adults with MCL
2.) Evaluate emerging data on targeted therapeutic approaches for treatment-naive and relapsed/refractory MCL and their applicability to older adults
3.) Assess mechanisms of resistance to targeted therapies for MCL and their implications for treatment selection
Acute scrotum is a general term referring to an emergency condition affecting the contents or the wall of the scrotum.
There are a number of conditions that present acutely, predominantly with pain and/or swelling
A careful and detailed history and examination, and in some cases, investigations allow differentiation between these diagnoses. A prompt diagnosis is essential as the patient may require urgent surgical intervention
Testicular torsion refers to twisting of the spermatic cord, causing ischaemia of the testicle.
Testicular torsion results from inadequate fixation of the testis to the tunica vaginalis producing ischemia from reduced arterial inflow and venous outflow obstruction.
The prevalence of testicular torsion in adult patients hospitalized with acute scrotal pain is approximately 25 to 50 percent
Recomendações da OMS sobre cuidados maternos e neonatais para uma experiência pós-natal positiva.
Em consonância com os ODS – Objetivos do Desenvolvimento Sustentável e a Estratégia Global para a Saúde das Mulheres, Crianças e Adolescentes, e aplicando uma abordagem baseada nos direitos humanos, os esforços de cuidados pós-natais devem expandir-se para além da cobertura e da simples sobrevivência, de modo a incluir cuidados de qualidade.
Estas diretrizes visam melhorar a qualidade dos cuidados pós-natais essenciais e de rotina prestados às mulheres e aos recém-nascidos, com o objetivo final de melhorar a saúde e o bem-estar materno e neonatal.
Uma “experiência pós-natal positiva” é um resultado importante para todas as mulheres que dão à luz e para os seus recém-nascidos, estabelecendo as bases para a melhoria da saúde e do bem-estar a curto e longo prazo. Uma experiência pós-natal positiva é definida como aquela em que as mulheres, pessoas que gestam, os recém-nascidos, os casais, os pais, os cuidadores e as famílias recebem informação consistente, garantia e apoio de profissionais de saúde motivados; e onde um sistema de saúde flexível e com recursos reconheça as necessidades das mulheres e dos bebês e respeite o seu contexto cultural.
Estas diretrizes consolidadas apresentam algumas recomendações novas e já bem fundamentadas sobre cuidados pós-natais de rotina para mulheres e neonatos que recebem cuidados no pós-parto em unidades de saúde ou na comunidade, independentemente dos recursos disponíveis.
É fornecido um conjunto abrangente de recomendações para cuidados durante o período puerperal, com ênfase nos cuidados essenciais que todas as mulheres e recém-nascidos devem receber, e com a devida atenção à qualidade dos cuidados; isto é, a entrega e a experiência do cuidado recebido. Estas diretrizes atualizam e ampliam as recomendações da OMS de 2014 sobre cuidados pós-natais da mãe e do recém-nascido e complementam as atuais diretrizes da OMS sobre a gestão de complicações pós-natais.
O estabelecimento da amamentação e o manejo das principais intercorrências é contemplada.
Recomendamos muito.
Vamos discutir essas recomendações no nosso curso de pós-graduação em Aleitamento no Instituto Ciclos.
Esta publicação só está disponível em inglês até o momento.
Prof. Marcus Renato de Carvalho
www.agostodourado.com
Prix Galien International 2024 Forum ProgramLevi Shapiro
June 20, 2024, Prix Galien International and Jerusalem Ethics Forum in ROME. Detailed agenda including panels:
- ADVANCES IN CARDIOLOGY: A NEW PARADIGM IS COMING
- WOMEN’S HEALTH: FERTILITY PRESERVATION
- WHAT’S NEW IN THE TREATMENT OF INFECTIOUS,
ONCOLOGICAL AND INFLAMMATORY SKIN DISEASES?
- ARTIFICIAL INTELLIGENCE AND ETHICS
- GENE THERAPY
- BEYOND BORDERS: GLOBAL INITIATIVES FOR DEMOCRATIZING LIFE SCIENCE TECHNOLOGIES AND PROMOTING ACCESS TO HEALTHCARE
- ETHICAL CHALLENGES IN LIFE SCIENCES
- Prix Galien International Awards Ceremony
Title: Sense of Taste
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the structure and function of taste buds.
Describe the relationship between the taste threshold and taste index of common substances.
Explain the chemical basis and signal transduction of taste perception for each type of primary taste sensation.
Recognize different abnormalities of taste perception and their causes.
Key Topics:
Significance of Taste Sensation:
Differentiation between pleasant and harmful food
Influence on behavior
Selection of food based on metabolic needs
Receptors of Taste:
Taste buds on the tongue
Influence of sense of smell, texture of food, and pain stimulation (e.g., by pepper)
Primary and Secondary Taste Sensations:
Primary taste sensations: Sweet, Sour, Salty, Bitter, Umami
Chemical basis and signal transduction mechanisms for each taste
Taste Threshold and Index:
Taste threshold values for Sweet (sucrose), Salty (NaCl), Sour (HCl), and Bitter (Quinine)
Taste index relationship: Inversely proportional to taste threshold
Taste Blindness:
Inability to taste certain substances, particularly thiourea compounds
Example: Phenylthiocarbamide
Structure and Function of Taste Buds:
Composition: Epithelial cells, Sustentacular/Supporting cells, Taste cells, Basal cells
Features: Taste pores, Taste hairs/microvilli, and Taste nerve fibers
Location of Taste Buds:
Found in papillae of the tongue (Fungiform, Circumvallate, Foliate)
Also present on the palate, tonsillar pillars, epiglottis, and proximal esophagus
Mechanism of Taste Stimulation:
Interaction of taste substances with receptors on microvilli
Signal transduction pathways for Umami, Sweet, Bitter, Sour, and Salty tastes
Taste Sensitivity and Adaptation:
Decrease in sensitivity with age
Rapid adaptation of taste sensation
Role of Saliva in Taste:
Dissolution of tastants to reach receptors
Washing away the stimulus
Taste Preferences and Aversions:
Mechanisms behind taste preference and aversion
Influence of receptors and neural pathways
Impact of Sensory Nerve Damage:
Degeneration of taste buds if the sensory nerve fiber is cut
Abnormalities of Taste Detection:
Conditions: Ageusia, Hypogeusia, Dysgeusia (parageusia)
Causes: Nerve damage, neurological disorders, infections, poor oral hygiene, adverse drug effects, deficiencies, aging, tobacco use, altered neurotransmitter levels
Neurotransmitters and Taste Threshold:
Effects of serotonin (5-HT) and norepinephrine (NE) on taste sensitivity
Supertasters:
25% of the population with heightened sensitivity to taste, especially bitterness
Increased number of fungiform papillae
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Oleg Kshivets
RESULTS: Overall life span (LS) was 2252.1±1742.5 days and cumulative 5-year survival (5YS) reached 73.2%, 10 years – 64.8%, 20 years – 42.5%. 513 LCP lived more than 5 years (LS=3124.6±1525.6 days), 148 LCP – more than 10 years (LS=5054.4±1504.1 days).199 LCP died because of LC (LS=562.7±374.5 days). 5YS of LCP after bi/lobectomies was significantly superior in comparison with LCP after pneumonectomies (78.1% vs.63.7%, P=0.00001 by log-rank test). AT significantly improved 5YS (66.3% vs. 34.8%) (P=0.00000 by log-rank test) only for LCP with N1-2. Cox modeling displayed that 5YS of LCP significantly depended on: phase transition (PT) early-invasive LC in terms of synergetics, PT N0—N12, cell ratio factors (ratio between cancer cells- CC and blood cells subpopulations), G1-3, histology, glucose, AT, blood cell circuit, prothrombin index, heparin tolerance, recalcification time (P=0.000-0.038). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and PT early-invasive LC (rank=1), PT N0—N12 (rank=2), thrombocytes/CC (3), erythrocytes/CC (4), eosinophils/CC (5), healthy cells/CC (6), lymphocytes/CC (7), segmented neutrophils/CC (8), stick neutrophils/CC (9), monocytes/CC (10); leucocytes/CC (11). Correct prediction of 5YS was 100% by neural networks computing (area under ROC curve=1.0; error=0.0).
CONCLUSIONS: 5YS of LCP after radical procedures significantly depended on: 1) PT early-invasive cancer; 2) PT N0--N12; 3) cell ratio factors; 4) blood cell circuit; 5) biochemical factors; 6) hemostasis system; 7) AT; 8) LC characteristics; 9) LC cell dynamics; 10) surgery type: lobectomy/pneumonectomy; 11) anthropometric data. Optimal diagnosis and treatment strategies for LC are: 1) screening and early detection of LC; 2) availability of experienced thoracic surgeons because of complexity of radical procedures; 3) aggressive en block surgery and adequate lymph node dissection for completeness; 4) precise prediction; 5) adjuvant chemoimmunoradiotherapy for LCP with unfavorable prognosis.
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?bkling
Are you curious about what’s new in cervical cancer research or unsure what the findings mean? Join Dr. Emily Ko, a gynecologic oncologist at Penn Medicine, to learn about the latest updates from the Society of Gynecologic Oncology (SGO) 2024 Annual Meeting on Women’s Cancer. Dr. Ko will discuss what the research presented at the conference means for you and answer your questions about the new developments.
Ethanol (CH3CH2OH), or beverage alcohol, is a two-carbon alcohol
that is rapidly distributed in the body and brain. Ethanol alters many
neurochemical systems and has rewarding and addictive properties. It
is the oldest recreational drug and likely contributes to more morbidity,
mortality, and public health costs than all illicit drugs combined. The
5th edition of the Diagnostic and Statistical Manual of Mental Disorders
(DSM-5) integrates alcohol abuse and alcohol dependence into a single
disorder called alcohol use disorder (AUD), with mild, moderate,
and severe subclassifications (American Psychiatric Association, 2013).
In the DSM-5, all types of substance abuse and dependence have been
combined into a single substance use disorder (SUD) on a continuum
from mild to severe. A diagnosis of AUD requires that at least two of
the 11 DSM-5 behaviors be present within a 12-month period (mild
AUD: 2–3 criteria; moderate AUD: 4–5 criteria; severe AUD: 6–11 criteria).
The four main behavioral effects of AUD are impaired control over
drinking, negative social consequences, risky use, and altered physiological
effects (tolerance, withdrawal). This chapter presents an overview
of the prevalence and harmful consequences of AUD in the U.S.,
the systemic nature of the disease, neurocircuitry and stages of AUD,
comorbidities, fetal alcohol spectrum disorders, genetic risk factors, and
pharmacotherapies for AUD.
1. HCS Pharma – Siège de Lille
Biocentre Fleming Bat A
250 rue Salvador Allende
59120 LOOS
BIOMIMESYS®
is a registered trademark
of HCS Pharma
+33 769 999 137
www.biomimesys.com
hello@biomimesys.com
Innovative Hydroscaffolds™ for 3D Cell Culture to better mimic the tissue microenvironment and
provide more predictive tools for drug development and metabolic studies
Other BIOMIMESYS® products available
PRODUCT
BIOMIMESYS® Oncology is a new generation of
mimetic Hydroscaffolds™ for 3D cell culture. Available in
a ready-to-use format, it enables the culture of cells
under physiological conditions that are representative of
the microenvironment found in whole tissues. The highly
porous structure of BIOMIMESYS® allows cells to diffuse
into the 3D matrix, where they can fix and begin to
develop. The structure and conformation of cells cultured
in BIOMIMESYS®, such as cancer cells that
spontaneously form spheroids, strongly resemble the
structures formed in vivo. Also, the functionality of the
BIOMIMESYS® matrix is proved by the expression of
genes and proteins at levels that are again more similar
to those found in vivo. Cells cultured in BIOMIMESYS® give results that are more physiological than
those grown in 2D culture and are closer to those obtained in vivo.
Figure 1: SEM picture
2. HCS Pharma – Siège de Lille
Biocentre Fleming Bat A
250 rue Salvador Allende
59120 LOOS
BIOMIMESYS®
is a registered trademark
of HCS Pharma
+33 769 999 137
www.biomimesys.com
hello@biomimesys.com
Hyaluronic acid (HA) being a major component of the cell’s extracellular matrix (ECM), BIOMIMESYS®
Hydroscaffolds™ for 3D cell culture is an ideal study model because it is:
Highly porous for the simple extraction of RNA and proteins
Biodegradable for easy cell retrieval
Transparent for direct visualization of cells
Representative of the cell microenvironment in terms of cell-cell interactions, cell-matrix
interactions and the expression of proteins and genes
BIOMIMESYS® Oncology is made of HYALURONIC ACID (HA), a glycosaminoglycan. Hyaluronic acid is a major
component of the extracellular matrix (ECM), and it plays an IMPORTANT ROLE in connective tissue.
The HA-based Hydroscaffolds™ are formed by crosslinking HA and type I collagen with ADH to form
reticulated chains.
High molecular weight Hyaluronic acid + type I collagen.
BIODEGRADABLE product.
PHYSICOCHEMICAL FEATURES
o Porosity: 150-200um
o Rheology: Young’s modulus: E= 1 kPa +/-Swelling ratio = 75 ± 10g/g
READY-TO-USE
BIOMIMESYS®
Hydroscaffolds™ technology is EASY to handle handling & READY-TO-USE. Upon receiving
the vacuum sealed 96-well plate open it (under a hood) and add the cells directly on top of the matrix.
Changing the culture medium is easy as well. To remove medium, simply draw the medium with a
pipette between the matrix and the edge of the well. To refresh the medium, place fresh medium onto
the surface of the matrix.
96-well plate format
10-40µl of cell
suspension
dropped on the
surface of
BIOMIMESYS®
Culture medium
is gently added
on the side of
the well to
obtain qs. 200µl
3. HCS Pharma – Siège de Lille
Biocentre Fleming Bat A
250 rue Salvador Allende
59120 LOOS
BIOMIMESYS®
is a registered trademark
of HCS Pharma
+33 769 999 137
www.biomimesys.com
hello@biomimesys.com
COMPATIBLE TECHNOLOGIES
BIOMIMESYS® Hydroscaffolds™ has many properties (translucent, porous, and biodegradable) that
make it ideal for use with numerous downstream applications. The growing cells are easily retrieved
from the matrix by a gentle and rapid procedure, this means that cells cultured in BIOMIMESYS® may
be analyzed using all technologies as shown below.
TRANSPARENT POROUS BIODEGRADABLE SOLID
Microscopy PCRs Flow cytometry Histology
Plate Reader (OD,
fluorescence,
luminescence
Western-Blot
ELISA
SUCESSFULLY TESTED CELLS
Cancer Cells Lines & Primary Tumors
Human brain metastasis SA87
Human breast adenocarcinoma MCF-7
Human breast carcinoma CAL-51
Human cervix adenocarcinoma HeLa
Human colorectal adenocarcinoma DLD-1, HT29, Caco-2
Human glioblastoma CB109 / CB74 / CB191
Human liver hepatocellular carcinoma HepG2
Human liver hepatoma PLC / PRF-5
Human lung carcinoma NCI-H460
Human osteosarcoma SaOs
Human ovarian carcinoma IGROV-1
Human pancreas carcinoma PANC-1
Human prostate cancer PC3
RELATED PUBLICATIONS
“DIRECT EFFECT OF BEVACIZUMAB ON GLIOBLASTOMA CELL LINES IN VITRO“. SIMON T., COQUEREL B., ET
AL. (2014) NEUROMOLECULAR MED.; 16(4):752-71
“SURVIVAL OF CORD BLOOD HAEMATOPOIETIC STEM CELLS IN A HYALURONAN HYDROGEL FOR EX VIVO
BIOMIMICRY”. DEMANGE E., KASSIM Y., ET AL. (2012) J TISSUE ENG REGEN MED 7(11):901-10
“ELASTIN-DERIVED PEPTIDES: MATRIKINES CRITICAL FOR GLIOBLASTOMA CELL AGGRESSIVENESS IN A 3-D
SYSTEM”. COQUEREL B., POYER F., ET AL. (2009). GLIA 57(16): 1716-26.
“COLLAGENS, STROMAL CELL-DERIVED FACTOR-1ALPHA AND BASIC FIBROBLAST GROWTH FACTOR
INCREASE CANCER CELL INVASIVENESS IN A HYALURONAN HYDROGEL”. DAVID L., DULONG V., ET AL. (2008).
CELL PROLIF 41(2): 348-64
4. HCS Pharma – Siège de Lille
Biocentre Fleming Bat A
250 rue Salvador Allende
59120 LOOS
BIOMIMESYS®
is a registered trademark
of HCS Pharma
+33 769 999 137
www.biomimesys.com
hello@biomimesys.com
“HYALURONAN HYDROGEL: AN APPROPRIATE THREE-DIMENSIONAL MODEL FOR EVALUATION OF
ANTICANCER DRUG SENSITIVITY.” DAVID L., DULONG V., ET AL. (2008). ACTA BIOMATER 4(2): 256-63
“RETICULATED HYALURONAN HYDROGELS: A MODEL FOR EXAMINING CANCER CELL INVASION IN 3D.”
DAVID L., DULONG V., ET AL. (2004). MATRIX BIOL 23(3): 183-93
PRICING
BIOMIMESYS® hydroscaffold is sold for RESEARCH USE ONLY.
96-WELL PLATE
**price per plate**
Quantity of 96-well plates 1 ≥ 10 ≥ 100 ≥ 1000
BIO_ONC_96_96_transp
(96 well plate with 96 Hydroscaffolds™)
BIO_ONC_96_24_transp
(96 well plate with 24 Hydroscaffolds™)
Quantity of 96-well *BLACK* plates 1 ≥ 10 ≥ 100 ≥ 1000
BIO_ONC_96_96_black
(96 well plate with 96 Hydroscaffolds™)
BIO_ONC_96_24_black
(96 well plate with 24 Hydroscaffolds™)
BIO_ONC_384_384_black
(384 well plate with 384 Hydroscaffolds™)
Contact Information
HCS Pharma
hello@biomimesys.com
http://www.biomimesys.com